Seer, a developer of protein analysis tools, prices upsized IPO at $19, above the range

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Dec 4, 2020 at 11:12 AM.

  1. #1 cafead, Dec 4, 2020 at 11:12 AM
    cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,990
    Likes Received:
    3
    via Seer, which is developing next-generation proteome analysis tests for biomedical research, raised $175 million by offering 9.2 million shares at $19, above the range of $16 to $18.

    article source
     
    Quote

Reply to Thread